Fig. 2: Crystal structure of pemigaitnib in complex with FGFR1.
From: Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
A Overall structure of the pemigatinib/FGFR1 complex. B The activation loop of pemigaitnib kept in DFG-in conformation. C Hydrogen-bond interaction between pemigatinib and FGFR1.
